FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018272010> ?p ?o ?g. }

• W2018272010 endingPage "1955" @default.
• W2018272010 startingPage "1951" @default.
• W2018272010 abstract "The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 months of first complete remission (CR); (2) AML refractory to chemotherapy at initial induction or at first relapse; (3) AML in second or greater relapse; (4) myeloid blast crisis of chronic myeloid leukemia (CML); (5) untreated patients > or = 70 years or > or = 55 years with abnormal cytogenetics (excluding inv 16, t(15;17) and t(8;21)) and/or an antecedent hematologic disorder; (6) refractory anemia with excess blasts in transformation (RAEBT). Forty-three patients, ages 19-84 (mean 62), were treated, including 7 patients with untreated AML age > 70 years, 2 with untreated RAEBT, 14 with AML first salvage (first remission 0-6 months), 15 with AML > or = second salvage and 14 with myeloid blast phase of CML. The overall response rate was 14%, with 4/43 (9%) patients achieving CR and 2/43 (5%) achieving CR without platelet recovery. The most significant toxicity was neutropenic fever, which occurred in 84% of patients. In conclusion, in patients with relapsed/refractory AML, gemtuzumab ozogamicin has a comparable response rate to single-agent chemotherapy and may offer a more favorable toxicity profile." @default.
• W2018272010 created "2016-06-24" @default.
• W2018272010 creator A5007205148 @default.
• W2018272010 creator A5012863731 @default.
• W2018272010 creator A5029569818 @default.
• W2018272010 creator A5030342776 @default.
• W2018272010 creator A5040539933 @default.
• W2018272010 creator A5040941721 @default.
• W2018272010 creator A5077726286 @default.
• W2018272010 creator A5083227554 @default.
• W2018272010 creator A5084409602 @default.
• W2018272010 creator A5085248404 @default.
• W2018272010 date "2002-01-01" @default.
• W2018272010 modified "2023-10-14" @default.
• W2018272010 title "Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia" @default.
• W2018272010 cites W174683914 @default.
• W2018272010 cites W183128447 @default.
• W2018272010 cites W1909698311 @default.
• W2018272010 cites W2000275771 @default.
• W2018272010 cites W2114165550 @default.
• W2018272010 cites W2123134392 @default.
• W2018272010 cites W2137696432 @default.
• W2018272010 cites W2165846604 @default.
• W2018272010 cites W2222947433 @default.
• W2018272010 cites W2263790816 @default.
• W2018272010 cites W2324265531 @default.
• W2018272010 cites W2410089930 @default.
• W2018272010 cites W2466569700 @default.
• W2018272010 cites W2764775166 @default.
• W2018272010 cites W3082443879 @default.
• W2018272010 cites W4244897830 @default.
• W2018272010 doi "https://doi.org/10.1080/1042819021000016078" @default.
• W2018272010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12481890" @default.
• W2018272010 hasPublicationYear "2002" @default.
• W2018272010 type Work @default.
• W2018272010 sameAs 2018272010 @default.
• W2018272010 citedByCount "31" @default.
• W2018272010 countsByYear W20182720102013 @default.
• W2018272010 countsByYear W20182720102014 @default.
• W2018272010 countsByYear W20182720102016 @default.
• W2018272010 countsByYear W20182720102018 @default.
• W2018272010 countsByYear W20182720102023 @default.
• W2018272010 crossrefType "journal-article" @default.
• W2018272010 hasAuthorship W2018272010A5007205148 @default.
• W2018272010 hasAuthorship W2018272010A5012863731 @default.
• W2018272010 hasAuthorship W2018272010A5029569818 @default.
• W2018272010 hasAuthorship W2018272010A5030342776 @default.
• W2018272010 hasAuthorship W2018272010A5040539933 @default.
• W2018272010 hasAuthorship W2018272010A5040941721 @default.
• W2018272010 hasAuthorship W2018272010A5077726286 @default.
• W2018272010 hasAuthorship W2018272010A5083227554 @default.
• W2018272010 hasAuthorship W2018272010A5084409602 @default.
• W2018272010 hasAuthorship W2018272010A5085248404 @default.
• W2018272010 hasConcept C10205521 @default.
• W2018272010 hasConcept C121332964 @default.
• W2018272010 hasConcept C126322002 @default.
• W2018272010 hasConcept C141071460 @default.
• W2018272010 hasConcept C142424586 @default.
• W2018272010 hasConcept C143998085 @default.
• W2018272010 hasConcept C176290653 @default.
• W2018272010 hasConcept C2776694085 @default.
• W2018272010 hasConcept C2778245361 @default.
• W2018272010 hasConcept C2778461978 @default.
• W2018272010 hasConcept C2778623314 @default.
• W2018272010 hasConcept C2778729363 @default.
• W2018272010 hasConcept C2779282312 @default.
• W2018272010 hasConcept C2780775027 @default.
• W2018272010 hasConcept C28328180 @default.
• W2018272010 hasConcept C29730261 @default.
• W2018272010 hasConcept C54355233 @default.
• W2018272010 hasConcept C71924100 @default.
• W2018272010 hasConcept C86803240 @default.
• W2018272010 hasConcept C87355193 @default.
• W2018272010 hasConcept C90924648 @default.
• W2018272010 hasConceptScore W2018272010C10205521 @default.
• W2018272010 hasConceptScore W2018272010C121332964 @default.
• W2018272010 hasConceptScore W2018272010C126322002 @default.
• W2018272010 hasConceptScore W2018272010C141071460 @default.
• W2018272010 hasConceptScore W2018272010C142424586 @default.
• W2018272010 hasConceptScore W2018272010C143998085 @default.
• W2018272010 hasConceptScore W2018272010C176290653 @default.
• W2018272010 hasConceptScore W2018272010C2776694085 @default.
• W2018272010 hasConceptScore W2018272010C2778245361 @default.
• W2018272010 hasConceptScore W2018272010C2778461978 @default.
• W2018272010 hasConceptScore W2018272010C2778623314 @default.
• W2018272010 hasConceptScore W2018272010C2778729363 @default.
• W2018272010 hasConceptScore W2018272010C2779282312 @default.
• W2018272010 hasConceptScore W2018272010C2780775027 @default.
• W2018272010 hasConceptScore W2018272010C28328180 @default.
• W2018272010 hasConceptScore W2018272010C29730261 @default.
• W2018272010 hasConceptScore W2018272010C54355233 @default.
• W2018272010 hasConceptScore W2018272010C71924100 @default.
• W2018272010 hasConceptScore W2018272010C86803240 @default.
• W2018272010 hasConceptScore W2018272010C87355193 @default.
• W2018272010 hasConceptScore W2018272010C90924648 @default.
• W2018272010 hasIssue "10" @default.
• W2018272010 hasLocation W20182720101 @default.
• W2018272010 hasLocation W20182720102 @default.

• next